The Evidence for Co-testing

Clinical data demonstrate that co-testing with Pap and HPV ordered together on the same accession provides the best protection against ≥CIN3 and cervical cancer for women ages 30 to 65, and recommendations from multiple leading health organizations support this conclusion. The results are in: co-testing is the most sensitive option for the most complete care. 

A landmark study from Quest Diagnostics HealthTrends™ used co-testing and cervical biopsy results to retrospectively compare Pap-alone testing, HPV-alone testing, and co-testing. The national study analyzed the de-identified data of approximately 8.6 million women ages 30 to 65 from thousands of clinical practices.1,2
 

  • Study population included 256,648 women who received both a co-test (Pap and HPV ordered together on the same accession) and cervical cancer biopsy performed by Quest Diagnostics within 1 year of each other
     
  • Visit GoWithCotesting.com to download a copy of the HealthTrends study by Blatt AJ, et al, from the May 2015 issue of Cancer Cytopathology

Learn more about the improved detection of ≥CIN3 and superior protection against cervical cancer that Pap and HPV testing offers, as well as the limitations of HPV-alone screening.

 

Dividing lineImproved detection of CIN3 and superior protection against cervical cancer
Co-testing missed the fewest cases of ≥CIN3 vs HPV-alone or Pap-alone testing.1,2

Percentage of missed by screening method

Back to top

Dividing line 

Co-testing (Pap and HPV) had the fewest missed cases of cervical cancers in the same HealthTrends study
 

Percentage of missed cases of cervical cancers by screening method

                                                                                                                                   Back to top

Dividing line

Limitations of HPV-alone screening


Numerous studies have shown screening with HPV alone misses cervical cancer in up to 31% of cases.1,2

Proportion of HPV cases chart

  • Clinical data from 10 published studies, including the Quest Diagnostics HealthTrends study, show that co-testing (Pap and HPV ordered together on the same accession) offers the best protection for your patients1,2

 

Back to top

References:

1. Blatt AJ, Kennedy R, Luff RD, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathology. 2015;123(5):282-288.

2. Quest Diagnostics. Data on file. 2015.